VOR:NASDAQ, Vor Biopharma Inc.
VOR stock overview
Vor Biopharma Inc. (VOR:NASDAQ) closed at $19.19 on November 20, 2026,
up 3.62% on the day.
The stock trades 26.2% below its 52-week high of $26.00
and 186.8% above its 52-week low of $6.69.
Over the past year, it gained 157.6%.
Vor Biopharma Inc. is part of the Health Care sector.
Key figures
- Price
- $19.19
- Day change
- +3.62%
- Volume
- 1,554,050
- Average volume
- 931,032
- Market cap
- 1B+
- 52-week range
- $6.69 – $26.00
- 50-day average
- $19.55
- 200-day average
- $17.64
Price action over the past year
In 252 trading sessions since November 20, 2025, VOR closed higher on 120 days (48%).
Its best day was December 9, 2025 (+28.23%) and its worst was November 20, 2025 (-12.28%).
The stock moved 10% or more in a single session 23 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
VOR news
-
Nov 13, 2026:
Is Narrower Quarterly Loss Altering The Investment Case For Vor Biopharma Stock?
-
Nov 12, 2026:
Vor Biopharma Adds RC298 to RemeGen License Deal
-
Nov 12, 2026:
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
-
Nov 10, 2026:
Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference
-
Nov 6, 2026:
Vor Biopharma (VOR) Stock Looks Reasonable After a 94% Five Year Slide
-
Nov 4, 2026:
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Oct 30, 2026:
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
-
Oct 22, 2026:
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
About Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Similar stocks
Find more stocks like VOR with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.